諾瓦瓦克斯醫藥 NVAX 深 滬
等待開盤 08-21 09:30:00 美东时间
8.74
-0.780
-8.19%
華盛通- 最 高9.20
- 今 開8.72
- 成交量 643.76万股
- 最 低 8.55
- 昨 收 9.52
- 總市值 14.16亿
- 52周最高 15.22
- 市盈率 靜 --
- 換手率 3.97%
- 52周最低 5.01
- 委 比 -58.17%
- 總股本 1.62亿
- 歷史最高 331.68
- 量 比 0.87
- 振 幅 6.83%
- 歷史最低 3.5324
- 每 手 1
- 風險率 2.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the S&P 500 futur...
08-20 20:27
Novavax Stock Soars Amid Strategic Milestones
Novavax ( ($NVAX) ) has risen by 19.30%. Read on to learn why. Novavax has seen...
08-16 22:03
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy.
08-13 01:41
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
08-11 20:45
FDA争议官员回归引爆抛售潮！美股生物科技板块盘前下挫
周一美股盘前，多家生物科技公司股价出现下跌。此前有报道称，曾被解职的美国食品药品监督管理局(FDA)疫苗监管官员Vinay Prasad将重返该机构。
08-11 19:42
Biotech sector slips amid reported return of ousted FDA official
Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency. Prasad, who had o...
08-11 18:25
FDA reinstates top vaccines regulator just days after his abrupt departure
At the U.S. Food and Drug Administration's (FDA) request, Vinay Prasad is returning to the role of director of the Center for Biologics Evaluation and Research, just ten days after departing the agenc...
08-10 04:46
Novavax Stock Surges Amid Strategic Gains
Novavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has expe...
08-09 22:03
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales
Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi.
08-06 22:48
